Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too

Photo: Noam Solomon and Luis Voloch (Immunai). Article by Darrell Etherington. TechCrunch – February 11, 2021.

Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Despite its youth, Immunai has already established the largest database in the world for single cell immunity characteristics, and it has already used its machine learning-powered immunity analysts platform to enhance the performance of existing immunotherapies. Aided by this new funding, it’s now ready to expand into the development of entirely new therapies based on the strength and breadth of its data and ML. […]

Click here to view original web page at techcrunch.com

Related articles:

Wading deeper into target discovery and validation, Immunai bags $60M to beef up both AI algorithms and lab benches – Endpoints

Immunai – Crunchbase

Immunai raises $60 million to analyze the immune system with AI – VentureBeat –

Israel’s Immunai hopes to reprogram immune system with $60m. funding – The Jerusalem Post

Biotech firm Immunai raises $60 million in private funding round – Reuters